Pompe Disease: Early Diagnosis and Early Treatment Make a Difference
Tóm tắt
Từ khóa
Tài liệu tham khảo
Hirschhorn, 2001, Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency, 3389
Pompe, 1932, Over idiopatische hypertrophie van het hart, Ned Tijdshr Geneeskd, 76, 304
Van den Hout, 2004, Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk, Pediatrics, 113, e448, 10.1542/peds.113.5.e448
Kishnani, 2007, Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease, Neurology, 68, 99, 10.1212/01.wnl.0000251268.41188.04
Kishnani, 2006, A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease, J Pediatr, 148, 671, 10.1016/j.jpeds.2005.11.033
Hagemans, 2005, Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients, Brain, 128, 671, 10.1093/brain/awh384
Kroos, 2007, Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype, Neurology, 68, 110, 10.1212/01.wnl.0000252798.25690.76
Yang, 2011, Rapid progressive course of later-onset Pompe disease in Chinese patients, Mol Genet Metab, 104, 284, 10.1016/j.ymgme.2011.06.010
Ausems, 1999, Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling, Eur J Hum Genet, 7, 713, 10.1038/sj.ejhg.5200367
Lin, 1987, Pompe's disease in Chinese and prenatal diagnosis by determination of alpha-glucosidase activity, J Inherit Metab Dis, 10, 11, 10.1007/BF01799482
Bashan, 1988, Glycogen storage disease type II in Israel, Isr J Med Sci, 24, 224
Martiniuk, 1998, Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease, Am J Med Genet, 79, 69, 10.1002/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K
Ausems, 1999, Glycogen storage disease type II: birth prevalence agrees with predicted genotype frequency, Community Genet, 2, 91, 10.1159/000016192
Chien, 2008, Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program, Pediatrics, 122, e39, 10.1542/peds.2007-2222
Chien, 2011, Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening, J Pediatr, 158, 1023, 10.1016/j.jpeds.2010.11.053
Chiang, 2012, Algorithm for Pompe disease newborn screening: results from the taiwan screening program, Mol Genet Metab, 106, 281, 10.1016/j.ymgme.2012.04.013
Mechtler, 2012, Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria, Lancet, 379, 335, 10.1016/S0140-6736(11)61266-X
Wisselaar, 1993, Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation, J Biol Chem, 268, 2223, 10.1016/S0021-9258(18)53985-5
Kroos, 2012, Update of the Pompe disease mutation database with 60 novel GAA sequence variants and additional studies on the functional effect of 34 previously reported variants, Hum Mutat, 33, 1161, 10.1002/humu.22108
Boerkoel, 1995, Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II, Am J Hum Genet, 56, 887
Ko, 1999, Molecular genetic study of Pompe disease in Chinese patients in Taiwan, Hum Mutat, 13, 380, 10.1002/(SICI)1098-1004(1999)13:5<380::AID-HUMU6>3.0.CO;2-A
Kroos, 2012, The genotype-phenotype correlation in Pompe disease, Am J Med Genet C Semin Med Genet, 160, 59, 10.1002/ajmg.c.31318
Shieh, 1998, Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: evidence for a founder effect, Hum Mutat, 11, 306, 10.1002/(SICI)1098-1004(1998)11:4<306::AID-HUMU8>3.0.CO;2-S
Shigeto, 2011, Improved assay for differential diagnosis between Pompe disease and acid alpha-glucosidase pseudodeficiency on dried blood spots, Mol Genet Metab, 103, 12, 10.1016/j.ymgme.2011.01.006
Tajima, 2007, Structural and biochemical studies on Pompe disease and a “pseudodeficiency of acid alpha-glucosidase”, J Hum Genet, 52, 898, 10.1007/s10038-007-0191-9
Huie, 1996, Identification of an E689K substitution as the molecular basis of the human acid alpha-glucosidase type 4 allozyme (GAA*4), Ann Hum Genet, 60, 365, 10.1111/j.1469-1809.1996.tb00433.x
Kroos, 2008, p.[G576S; E689K]: pathogenic combination or polymorphism in Pompe disease?, Eur J Hum Genet, 16, 875, 10.1038/ejhg.2008.34
Yue, 2005, Loss of protein structure stability as a major causative factor in monogenic disease, J Mol Biol, 353, 459, 10.1016/j.jmb.2005.08.020
Yue, 2006, Identification and analysis of deleterious human SNPs, J Mol Biol, 356, 1263, 10.1016/j.jmb.2005.12.025
Hermans, 1993, Human lysosomal alpha-glucosidase: functional characterization of the glycosylation sites, Biochem J, 289, 681, 10.1042/bj2890681
Labrousse, 2010, Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program, Mol Genet Metab, 99, 379, 10.1016/j.ymgme.2009.12.014
Taniguchi, 1978, Alpha-glucosidase activity in human leucocytes: choice of lymphocytes for the diagnosis of Pompe's disease and the carrier state, Clin Chim Acta, 89, 293, 10.1016/0009-8981(78)90328-5
Shin, 1985, Diagnosis of Pompe's disease using leukocyte preparations. Kinetic and immunological studies of 1,4-alpha-glucosidase in human fetal and adult tissues and cultured cells, Clin Chim Acta, 148, 9, 10.1016/0009-8981(85)90295-5
Umapathysivam, 2005, Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease, Clin Chim Acta, 361, 191, 10.1016/j.cccn.2005.05.025
Umapathysivam, 2000, Determination of acid alpha-glucosidase protein: evaluation as a screening marker for Pompe disease and other lysosomal storage disorders, Clin Chem, 46, 1318, 10.1093/clinchem/46.9.1318
Chamoles, 2004, Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper, Clin Chim Acta, 347, 97, 10.1016/j.cccn.2004.04.009
Li, 2004, Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening, Clin Chem, 50, 1785, 10.1373/clinchem.2004.035907
Okumiya, 2006, A new diagnostic assay for glycogen storage disease type II in mixed leukocytes, Mol Genet Metab, 88, 22, 10.1016/j.ymgme.2005.10.016
Bijvoet, 1996, Expression of cDNA-encoded human acid alpha-glucosidase in milk of transgenic mice, Biochim Biophys Acta, 1308, 93, 10.1016/0167-4781(96)00093-0
Van Hove, 1996, High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease, Proc Natl Acad Sci U S A, 93, 65, 10.1073/pnas.93.1.65
van der Ploeg, 2010, A randomized study of alglucosidase alfa in late-onset Pompe's disease, N Engl J Med, 362, 1396, 10.1056/NEJMoa0909859
Nicolino, 2009, Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease, Genet Med, 11, 210, 10.1097/GIM.0b013e31819d0996
Kikuchi, 1998, Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase-deficient quail, J Clin Invest, 101, 827, 10.1172/JCI1722
Prater, 2012, The emerging phenotype of long-term survivors with infantile Pompe disease, Genet Med, 14, 800, 10.1038/gim.2012.44
Hunley, 2004, Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease, Pediatrics, 114, e532, 10.1542/peds.2003-0988-L
Banugaria, 2011, The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease, Genet Med, 13, 729, 10.1097/GIM.0b013e3182174703
Orsini, 2012, Lysosomal storage disorder 4+1 multiplex assay for newborn screening using tandem mass spectrometry: application to a small-scale population study for five lysosomal storage disorders, Clin Chim Acta, 413, 1270, 10.1016/j.cca.2012.04.012
Parkinson-Lawrence, 2006, Immunochemistry of lysosomal storage disorders, Clin Chem, 52, 1660, 10.1373/clinchem.2005.064915
Millington, 2010, Digital microfluidics: a future technology in the newborn screening laboratory?, Semin Perinatol, 34, 163, 10.1053/j.semperi.2009.12.008
Kishnani, 2009, Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease, Pediatr Res, 66, 329, 10.1203/PDR.0b013e3181b24e94
Chien, 2009, Pompe disease in infants: improving the prognosis by newborn screening and early treatment, Pediatrics, 124, e1116, 10.1542/peds.2008-3667
Chen, 2009, Reversal of cardiac dysfunction after enzyme replacement in patients with infantile-onset Pompe disease, J Pediatr, 155, 10.1016/j.jpeds.2009.03.015
Chen, 2011, Left ventricular geometry, global function, and dyssynchrony in infants and children with pompe cardiomyopathy undergoing enzyme replacement therapy, J Card Fail, 17, 930, 10.1016/j.cardfail.2011.07.011
Kishnani, 2004, Pompe disease in infants and children, J Pediatr, 144, S35, 10.1016/j.jpeds.2004.01.053
Case, 2012, Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations, Am J Med Genet C Semin Med Genet, 160, 69, 10.1002/ajmg.c.31321
DeRuisseau, 2009, Neural deficits contribute to respiratory insufficiency in Pompe disease, Proc Natl Acad Sci U S A, 106, 9419, 10.1073/pnas.0902534106
Gambetti, 1971, Nervous system in Pompe's disease. Ultrastructure and biochemistry, J Neuropathol Exp Neurol, 30, 412, 10.1097/00005072-197107000-00008
Teng, 2004, Infantile-onset glycogen storage disease type II (Pompe disease): report of a case with genetic diagnosis and pathological findings, Chang Gung Med J, 27, 379
Raben, 2003, Enzyme replacement therapy in the mouse model of Pompe disease, Mol Genet Metab, 80, 159, 10.1016/j.ymgme.2003.08.022
Ebbink, 2012, Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy, Neurology, 78, 1512, 10.1212/WNL.0b013e3182553c11
Jones, 2010, Oropharyngeal dysphagia in infants and children with infantile Pompe disease, Dysphagia, 25, 277, 10.1007/s00455-009-9252-x
van Gelder, 2012, Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy, J Inherit Metab Dis, 35, 505, 10.1007/s10545-011-9404-7
Chien, 2006, Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy, Pediatr Res, 60, 349, 10.1203/01.pdr.0000233014.84318.4e
Raben, 2010, Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy, Mol Genet Metab, 101, 324, 10.1016/j.ymgme.2010.08.001
Thurberg, 2006, Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease, Lab Invest, 86, 1208, 10.1038/labinvest.3700484
Banugaria, 2012, Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells, Mol Genet Metab, 105, 677, 10.1016/j.ymgme.2012.01.019
Messinger, 2012, Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease, Genet Med, 14, 135, 10.1038/gim.2011.4
Bali, 2012, Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience, Am J Med Genet C Semin Med Genet, 160, 40, 10.1002/ajmg.c.31319
Hermans, 1993, The conservative substitution Asp-645–>Glu in lysosomal alpha-glucosidase affects transport and phosphorylation of the enzyme in an adult patient with glycogen-storage disease type II, Biochem J, 289, 687, 10.1042/bj2890687
Zhu, 2009, Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease, Mol Ther, 17, 954, 10.1038/mt.2009.37
LeBowitz, 2004, Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice, Proc Natl Acad Sci U S A, 101, 3083, 10.1073/pnas.0308728100
Maga, 2013, Glycosylation-independent lysosomal targeting of acid alpha-glucosidase enhances muscle glycogen clearance in pompe mice, J Biol Chem, 288, 1428, 10.1074/jbc.M112.438663
Parenti, 2009, Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics, EMBO Mol Med, 1, 268, 10.1002/emmm.200900036
Khanna, 2012, The pharmacological chaperone AT2220 increases recombinant human acid alpha-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease, PLoS One, 7, e40776, 10.1371/journal.pone.0040776
Porto, 2012, Pharmacological enhancement of alpha-glucosidase by the allosteric chaperone N-acetylcysteine, Mol Ther, 20, 2201, 10.1038/mt.2012.152
Amalfitano, 1999, Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase, Proc Natl Acad Sci U S A, 96, 8861, 10.1073/pnas.96.16.8861
Sun, 2008, Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy, Mol Ther, 16, 1366, 10.1038/mt.2008.133
van Til, 2010, Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype, Blood, 115, 5329, 10.1182/blood-2009-11-252874